Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells

被引:265
作者
Féraudet, C
Morel, N
Simon, S
Volland, H
Frobert, Y
Créminon, C
Vilette, D
Lehmann, S
Grassi, J [1 ]
机构
[1] CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France
[2] INRA, F-78350 Jouy En Josas, France
[3] CNRS, F-34396 Montpellier, France
关键词
D O I
10.1074/jbc.M407006200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prion diseases are transmissible neurodegenerative disorders affecting humans and animals for which no therapeutic or prophylactic regimens exist. During the last three years several studies have shown that anti-PrP monoclonal antibodies (mAbs) can antagonize prion propagation in vitro and in vivo, but the mechanisms of inhibition are not known so far. To identify the most powerful mAbs and characterize more precisely the therapeutic effect of anti-PrP antibodies, we have screened 145 different mAbs produced in our laboratory for their capacity to cure cells constitutively expressing PrPSc. Our results confirm for a very large series of antibodies that mAbs recognizing cell-surface native PrPc can efficiently clean and definitively cure infected cells. Antibodies having a cleaning effect are directed against linear epitopes located in at least four different regions of PrP, suggesting an epitope-independent inhibition mechanism. The consequence of antibody binding is the sequestration of PrPc at the cell surface, an increase of PrPc levels recovered in cell culture medium, and an internalization of antibodies. Taken together these data suggest that the cleaning process is more likely due to a global effect on the PrP trafficking and/or transconformation process. Two antibodies, Sha31 and BAR236, show an IC50 of 0.6 nM, thus appearing 10-fold more efficient than previous antibodies described in the literature. Finally, five co-treatments were also tested, and only one of them, described previously (SAF34 + SAF61), lowered PrPSc levels in the cells synergistically.
引用
收藏
页码:11247 / 11258
页数:12
相关论文
共 55 条
[1]   Mammalian prion biology: One century of evolving concepts [J].
Aguzzi, A ;
Polymenidou, M .
CELL, 2004, 116 (02) :313-327
[2]   PrPSc binding antibodies are potent inhibitors of prion replication in cell lines [J].
Beringue, V ;
Vilette, D ;
Mallinson, G ;
Archer, F ;
Kaisar, M ;
Tayebi, M ;
Jackson, GS ;
Clarke, AR ;
Laude, H ;
Collinge, J ;
Hawke, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (38) :39671-39676
[3]   Drug therapy in human and experimental transmissible spongiform encephalopathy [J].
Brown, P .
NEUROLOGY, 2002, 58 (12) :1720-1725
[4]   Detection of variant Creutzfeld-Jakob disease infectivity in extraneural tissues [J].
Bruce, ME ;
McConnell, I ;
Will, RG ;
Ironside, JW .
LANCET, 2001, 358 (9277) :208-209
[5]   Prion diseases - Close to effective therapy? [J].
Cashman, NR ;
Caughey, B .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (10) :874-884
[6]   New insight into abnormal prion protein using monoclonal antibodies [J].
Demart, S ;
Fournier, JG ;
Creminon, C ;
Frobert, Y ;
Lamoury, F ;
Marce, D ;
Lasmézas, C ;
Dormont, D ;
Grassi, J ;
Deslys, JP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 265 (03) :652-657
[7]   Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody [J].
Enari, M ;
Flechsig, E ;
Weissmann, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9295-9299
[8]   Promising developments bringing prion diseases closer to therapy and prophylaxis [J].
Gilch, S ;
Schätzl, HM .
TRENDS IN MOLECULAR MEDICINE, 2003, 9 (09) :367-369
[9]   Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells [J].
Gilch, S ;
Wopfner, F ;
Renner-Müller, I ;
Kremmer, E ;
Bauer, C ;
Wolf, E ;
Brem, G ;
Groschup, MH ;
Schätzl, HM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (20) :18524-18531
[10]  
Grassi J, 1996, CLIN CHEM, V42, P1532